Beta-L-FddC

Drug Profile

Beta-L-FddC

Alternative Names: 5-F-b-L-ddC; 5-F-beta-L-ddC

Latest Information Update: 05 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source
  • Developer Nonindustrial source; Shire Pharmaceuticals Group; Vion Pharmaceuticals
  • Class
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis B; HIV infections

Most Recent Events

  • 05 Jun 2001 BioChem Pharma has been acquired by Shire Pharmaceuticals Group
  • 18 Dec 1998 Preclinical development for HIV infections treatment in USA (Unknown route)
  • 05 Oct 1998 Preclinical development for Hepatitis B in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top